WallStreetZenWallStreetZen

NASDAQ: TBPH
Theravance Biopharma Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Theravance Biopharma earnings were $29.3M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest TBPH earnings report on Sep 30, 2025 announced Q3 2025 earnings of $3.6M, down 93.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TBPH reported annual earnings of -$56.4M, with 2.2% growth. The next TBPH earnings date is Mar 2, 2026.

TBPH past earnings growth

How has TBPH's earnings growth performed historically?

Company
N/A
Industry
59.87%
Market
55.77%
TBPH's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
TBPH's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

TBPH earnings history

Current Revenue
$80.3M
Current Earnings
$29.3M
Current Profit Margin
36.5%

TBPH Return on Equity

Current Company
14.7%
Current Industry
-21.2%
Current Market
35.1%
TBPH's Return on Equity (14.7%)... subscribe to Premium to read more.
High Return on Equity Performance

TBPH Return on Assets

Current Company
7.6%
Current Industry
-8.8%
TBPH is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TBPH announces earnings.

TBPH Return on Capital Employed

Current Company
13.16%
Current Industry
-3.5%
TBPH's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TBPH vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TBPH$55.37M$29.34M-98.26%$0.58
CTMX$33.92M$28.02M+141.18%$0.41
PVLA-$27.96M-$35.07MN/A-$1.62
URGN-$144.14M-$164.64MN/A-$3.26
PHAT-$203.56M-$274.55MN/A-$3.77
View Top Biotech Stocks

TBPH earnings dates

Next earnings date
Mar 2, 2026

Theravance Biopharma Earnings Reports & History FAQ

What were Theravance Biopharma's earnings last quarter?

On TBPH's earnings call on Invalid Date, Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 earnings per share (EPS) of $0.07, up 126.92% year over year. Total TBPH earnings for the quarter were $3.62 million. In the same quarter last year, Theravance Biopharma's earnings per share (EPS) was -$0.26.

If you're new to stock investing, here's how to buy Theravance Biopharma stock.

When does Theravance Biopharma report earnings?

The next TBPH earnings call is Invalid Date. Add TBPH to your watchlist to be reminded of Theravance Biopharma's next earnings date.

Is Theravance Biopharma profitable or losing money?

As of the last Theravance Biopharma earnings report, Theravance Biopharma is currently profitable. Theravance Biopharma's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $29.34 million, a 159.4% decrease year over year.

What was TBPH's earnings growth in the past year?

As of Theravance Biopharma's earnings date in Invalid Date, Theravance Biopharma's earnings has grown year over year. TBPH earnings in the past year totalled $29.34 million.

What are Theravance Biopharma's earnings expectations?

The current EPS estimate for Theravance Biopharma's earnings report in Invalid Date is $0.61.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.